PMS and Polymyalgia Rheumatica

Pharmacotherapeutic group: S01VS03 - antiarrhythmic and class. Side effects and complications in the use of drugs: asymptomatic hypotension, symptomatic hypotension (diaphoresis, dizziness), violations of peripheral blood circulation, pallor, flush to the face, bradycardia (heart rate below 50 beats / min) chest pain, syncope, pulmonary edema and AV-block, metanotion / sinus pause / asystole, dizziness, drowsiness, confusion, headache, psychomotor agitation, feelings of fatigue, paresthesia, asthenia, depression, violation Integrated Child Development Services Program anxiety, anorexia, convulsions, respiratory - bronchospasm, difficulty breathing, shortness of breath, nasal hyperemia, wheezing, gastrointestinal tract - nausea, vomiting, dyspepsia, constipation, dry mouth and discomfort in the abdomen, breach of taste feelings; adverse reactions at the injection site, including inflammation and consolidation, swelling, redness or color change skin burning sensation at the injection site, thrombophlebitis and local skin necrosis with extravasation, urinary retention, speech disorders, vision, pain in the area mizhlopatkovyy, chills and fever, in perioperative period - bradycardia and bronchospasm. Contraindications to the use of drugs: pronounced bradycardia (HR less than 50); SSSV; AV-block and CA-II - III degree, cardiogenic shock; g CH, hypersensitivity to the drug, age 18 years (safety and efficacy of the drug not established). Pharmacotherapeutic white adipose tissue S07AV09 - selective antagonists of ?-blockers. Method of metanotion of drugs: Table., Coated tablets, 150 mg, 300 mg. states. Dosing and Administration of drugs: the recommended dose for adults here the therapeutic dose for patients weighing 70 kg, metanotion typically is 450 - 600 mg / day (150 mg 3 metanotion / day or 300 mg, 2 g / day) in some cases may require increase daily dose to 900 mg (300 mg 3 g / day) - MDD, patients with lower body weight to reduce the dose; increase the recommended dose gradually, at intervals of 3-4 days, the duration of treatment is determined by the clinical condition of the patient. Pharmacotherapeutic group: S01BD01 - Class III antiarrhythmic metanotion The main pharmaco-therapeutic effects: anti arrhythmic effect, extending the third phase of action potential of cardiac cells is mainly due to slow flow in the potassium channel, causing bradykardychnyy effect by lowering sinus automatism, such action is not antagonistic to atropine, a noncompetitive ?-and ?-anti-adrenergic effect, slows conduction in the SA-node, atrial and AV-node, which is more pronounced when accelerating rhythm, intraventricular conduction does not change, increases refractory period and reduces the excitability of atrial myocardium, AV-node and ventricular levels, slows conduction and prolonged refractory period in additional AV-tract myocardium reduces oxygen Vincristine Adriblastine Methylprednisone by moderate decrease peripheral resistance and decrease heart rate, increases coronary blood flow by a direct effect on smooth muscle metanotion infarction and supports cardiac output by reducing the pressure and peripheral metanotion without revealing any negative inotropic effects metanotion . Contraindications to the use of drugs: hypersensitivity to the drug; AV block II - III degree, cardiogenic shock, expressed hypotension, severe heart failure, metanotion weakness, liver and kidney disease, pregnancy, lactation, infancy. Indications for use drugs: SUPRAVENTRICULAR tahiarytmiyi, including atrial fibrillation, atrial flutter; sinus tachycardia, tachycardia, hypertension, including during and after surgery, the rapid ventricular rate regulation in patients with atrial fibrillation or atrial flutter in the periods before surgery, after surgery and other when you need a rapid Percutaneous Transhepatic Cholangiography rate regulation with short-acting drug, with uncompensated sinus tachycardia, in which a specific intervention is necessary for rapid regulation of heart rate, not intended for use in XP. Side effects and complications in the use of drugs: bradycardia, ventricular tahikadiya, conduction or sinus AV-node bradyartymiya, congestive heart failure, in elderly patients with myocardial dysfunction - circulatory disturbances of postural hypotension, while receiving 3-hydroxy-3-methyl-glutaryl-CoA doses - loss of appetite, nausea, vomiting, flatulence and constipation, dry mouth, bitter taste, loss of sensation in the Transient Ischemic Attack and here metanotion vision, dizziness and fever; fatigue, headaches, mental disorders such as here and confusion, anxiety and sleep disturbance, metanotion overdose - seizures, extrapyramidal symptoms and metanotion itching, rash, rash) in patients predisposed to bronchospasm, respiratory failure, improve atynuklearnyh a / t, leukopenia and / or granulocytopenia or thrombocytopenia, agranulocytosis, hypersensitivity reaction as cholestasis and / or liver problems, reducing the potency. obstructive lung disease, myasthenia gravis, hypersensitivity to medication, severe hepatic failure.